Core Viewpoint - The article discusses the establishment of the second phase of the Service Trade Innovation Development Guidance Fund, which aims to support the growth of service trade enterprises in China, particularly in the context of foreign trade and digital economy [2][8]. Fund Overview - The total scale of the Service Trade Fund Phase II is set at 10 billion yuan, with a duration of up to 15 years [4][3]. - Key contributors include the Ministry of Finance (2 billion yuan), Shenzhen Investment (1.9 billion yuan), and Hangzhou Industrial Investment (1.5 billion yuan), among others [4][5]. Investment Strategy - The fund will adopt a "mother fund + direct investment" approach, with at least 70% allocated to sub-funds and no more than 30% for direct investments [5][6]. - It will focus on key areas outlined in the "Guidance Catalog for Key Areas of Service Exports" and "Key Development Areas for Service Outsourcing," supporting new business models in health technology, cross-border e-commerce, and digital economy [6][7]. Historical Context - The Service Trade Fund is recognized as the first national-level mother fund in the foreign trade sector, initiated in 2016 to broaden financing channels for service trade enterprises [8][9]. - The first phase of the fund was established with a total scale of 30 billion yuan, primarily targeting digital economy and logistics technology [8]. Market Conditions - The fundraising environment for VC/PE in China remains challenging, with a significant decline in the number and scale of newly raised funds in 2024 compared to previous years [11][13]. - Government funding has become a primary source of capital, while private LPs have become increasingly cautious, impacting the overall fundraising landscape [13].

日前，小商品城、昭衍新药等多家上市公司发布公告披露参与设立产业基金的进展。 小商品城在公告中指出：近日，公司与招商局资本管理（北京）有限公司及参与本基金的其他合伙 人共同签署了《合伙协议》，协议主要内容如下： 1、合伙目的 围绕创新服务贸易发展机制、发展数字贸易，加强与社会资本的协同配合，有效发挥 财政资金的政策引导和杠杆放大效应，带动社会资本支持服务贸易创新发展，推动数字贸易改革创 新发展，培育外贸新业态新模式，激发服务贸易发展新动能，推进贸易强国建设。 2、合伙期限 本合伙企业工商登记的合伙期限最长为十五（15）年，自《营业执照》载明的成立日 期起算。虽有前述约定，普通合伙人可根据全体合伙人的一致意见，报请商务部、财政部按程序研 究确定延长或提前终止本合伙企业的合伙期限。 3、出资方式 （1）所有合伙人之出资方式均为以人民币现金出资。 （2）全体合伙人同意，本合伙企业的各合伙人应于普通合伙人根据本合伙企业项目投资的具体资 金需求情况签发的各期缴付出资通知书分期进行缴付，每期的缴付出资由全体合伙人按实际认缴出 资比例缴付。为各期出资缴付之目的，普通合伙人将提前向各合伙人发出该期缴付出资通知书，列 明该合伙人 ...

投资界-解码LP获悉，昭衍新药发布公告，公司以不超过1亿元投资参与服务贸易创新发展引导基金二期 （有限合伙）（暂定名，简称"服贸二期基金"） 的发起设立，近日，公司全资子公司北京昭衍管理科 技有限公司与招商局资本管理（北京）有限公司及其他合伙人共同签署了《合伙协议》。 据公告披露，基金围绕创新服务贸易发展机制、发展数字贸易，加强与社会资本的协同配合，有效发挥 财政资金的政策引导和杠杆放大效应，带动社会资本支持服务贸易创新发展，推动数字贸易改革创新发 展，培育外贸新业态新模式，激发服务贸易发展新动能，推进贸易强国建设。 基金认缴出资额为100亿元，主要经营场所位于杭州市萧山区，存续期限最长为15年，招商局资本（北 京）作为基金管理人向合伙企业提供投资管理服务。 据悉，服务贸易创新发展引导基金成立于2017年11月，是经国务院批准，由财政部、商务部、招商局资 本等发起设立的国家级产业投资基金。基金总规模300亿元，首期100.08亿元，是国家首只投向服务贸 易领域的政府投资引导基金，重点投资于经国务院批准的《服务出口重点领域指导目录》和《服务外包 产业重点发展领域指导目录》列明的重点领域，以及商务部等部门文件中明 ...

Group 1 - The medical and pharmaceutical sector continues to perform strongly, with the Hong Kong medical ETF (159366) rising over 2% in early trading, marking a three-day increase [1] - Key stocks such as Kelaiying, Micron Medical, and Zhaoyan Pharmaceutical saw significant gains of 5.90%, 5.47%, and 4.73% respectively, contributing to a cumulative increase of 6.32% in the ETF over the past week [1] - A major policy announcement from the Central Committee and the State Council aims to improve public welfare and healthcare, including the establishment of a drug catalog adjustment mechanism and the promotion of quality healthcare resource sharing [1] Group 2 - Dongwu Securities highlights three factors that suggest 2025 will be a pivotal year for innovative drugs, including the orderly rollout of significant business development (BD) deals, expected profitability for more companies by 2026, and an improving domestic environment for innovative drugs [2] - The Chinese innovative drug market is poised for rapid growth, supported by favorable policies and international expansion, making it a highly promising sub-sector within the pharmaceutical industry [2] - The Hong Kong medical ETF (159366) focuses on unique medical segment leaders, including internet healthcare, CXO, and medical devices, and operates as a pure Hong Kong Stock Connect ETF with T+0 trading support [2]

Overview - The core point of the announcement is that Beijing Zhaoyan New Drug Research Center Co., Ltd. has approved an investment of up to 100 million RMB to participate in the establishment of the second phase of the Service Trade Innovation Development Guidance Fund, in collaboration with professional investment institutions [2][3]. Group 1: Fund Establishment - The company will invest in the Service Trade Innovation Development Guidance Fund Phase II, which aims to enhance the development of innovative service trade mechanisms and digital trade [3]. - The fund will be managed by China Merchants Capital Management (Beijing) Co., Ltd., which will act as the general partner and executive partner [2][3]. Group 2: Partnership Agreement - A partnership agreement has been signed among the company’s wholly-owned subsidiary, China Merchants Capital Management, and other partners, outlining the purpose of the partnership to leverage fiscal funds to stimulate social capital support for service trade innovation [3][4]. - The partnership has a maximum duration of 15 years, with provisions for extension or early termination based on unanimous agreement among partners [4]. Group 3: Investment Strategy - The fund will focus on private equity investments in service trade and digital trade sectors, as well as directly investing in relevant enterprises [9][10]. - Investments will be made through equity or equity-related debt instruments [10]. Group 4: Management and Fees - The fund will incur management fees, calculated based on a specified rate and the duration of the management period [8]. - An investment decision-making committee will be established to oversee investment and exit decisions [12]. Group 5: Fund Details - The fund is named the Service Trade Innovation Development Guidance Fund Phase II (tentative) and will operate as a limited partnership [15]. - The fund's operational scope includes private equity investment, investment management, asset management, and investment consulting [15].

证券简称：昭衍新药 证券代码：603127 公告编号：2025-023 北京昭衍新药研究中心股份有限公司 关于与专业投资机构合作参与投资设立产业基金 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、与专业投资机构合作参与投资设立产业基金情况概述 北京昭衍新药研究中心股份有限公司（以下简称"昭衍新药"、"公司"）于 2024 年 10 月 30 日召开第四届董事会第十次会议，审议通过了《关于公司与专业投资 机构合作参与投资设立产业基金的议案》，同意公司或指定子公司以不超过 1 亿元人民币投资参与服务贸易创新发展引导基金二期（有限合伙）（暂定名，具 体名称以工商行政管理机构核定名称为准，以下简称"服贸二期基金"、"本基金"） 的发起设立。招商局资本管理（北京）有限公司为本基金的普通合伙人、执行事 务合伙人，并担任本基金的基金管理人。具体内容详见公司于 2024 年 10 月 30 日在上海证券交易所网站（www.sse.com.cn）及指定信息披露媒体《上海证券报》 披露的《昭衍新药关于与专业投资机构合作参与投资设 ...

昭衍新药（603127）公告，公司全资子公司北京昭衍管理科技有限公司与招商局资本管理(北京)有限公 司及其他合伙人共同签署了《合伙协议》。该产业基金名为服务贸易创新发展引导基金二期(有限合 伙)，主要经营场所位于杭州市萧山区，存续期限最长为15年。合伙人包括中华人民共和国财政部、深 圳市招服投资有限责任公司等，北京昭衍管理科技有限公司认缴出资额为1亿元，占比1.00%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年6月9日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...

致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2025年6月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年5月31日 狀態: 新提交 | 2. 股份分類 | 普通股 | 股份類別 | A | ...

Core Viewpoint - The Hong Kong stock market is expected to open higher, with a positive pre-market performance in the innovative drug sector, driven by significant approvals for new drugs in China [1] Group 1: Market Performance - The Hong Kong innovative drug index constituents saw notable gains, with Innovent Biologics rising over 6%, and other companies like Zai Lab and WuXi AppTec increasing by over 2% [1] - The Hong Kong innovative drug ETF (159567) experienced a net inflow of over 165 million yuan in the past 20 trading days, indicating high market enthusiasm [1] - The price-to-earnings ratio of the Hong Kong innovative drug index decreased from 64 times on February 21 to 27 times on June 4, highlighting improved value for investors [1] Group 2: Regulatory Developments - On May 29, the National Medical Products Administration of China approved 11 innovative drugs, including 7 first-class innovative drugs, marking a historic moment for the sector [1] - Over 20 first-class innovative drugs have been approved from January to May, setting a record for the same period in the past five years [1] - The Chinese pharmaceutical industry is transitioning from "follow-up innovation" to "global leadership," focusing on clinical value in key areas like targeted cancer therapies and immunotherapy [1] Group 3: Investment Opportunities - The innovative drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends like AI-enabled drug development and the expansion of domestic innovative drugs [1] - The innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from AI advancements and the introduction of new drug reimbursement policies [2] - The domestic innovative drug sector is expected to show strong growth and investment value in the first half of 2025, driven by ongoing international collaborations and the approval of new drugs [2]